ライフサイエンスコーパス: Ebola virus

1 ies and emergent infectious diseases such as Ebola virus.

2 ependent of virion entrapment in the case of Ebola virus.

3 ethods have been recently reported to detect Ebola virus.

4 e first national semen testing programme for Ebola virus.

5 way challenge with a mouse-adapted strain of Ebola virus.

6 d to have survived congenital infection with Ebola virus.

7 ranes in contrast to the matrix protein from Ebola virus.

8 parasites, either alone or concurrently with Ebola virus.

9 To address the potential that anti-Ebola virus activity was overlooked, type I and type II

10 s including crucial mutations in VP24 enable Ebola virus adaptation to new hosts.

11 ified 33 different mutations associated with Ebola virus adaptation to rodents in the proteins GP, NP

12 ach to analyze the mutations associated with Ebola virus adaptation to rodents to elucidate the deter

13 spiratory syncytial virus, dengue virus, and Ebola virus, among others.

14 iviral potential, including activity against Ebola virus and bat influenza A-like virus, and we descr

15 olymerase chain reaction for the presence of Ebola virus and Plasmodium species RNA.

16 ntrast to tetrameric predictions for VP35 of Ebola virus and to known structures of homologous protei

17 taining the target nucleic acid fragments of Ebola virus, and 8 CFU of Escherichia coli carrying Ebol

18 sistor method for real-time detection of the Ebola virus antigen.

19 Ebola viruses are not pathogenic but can be adapted to r

20 sses the host response against influenza and Ebola viruses as well as bacterial products.

21 t part in reducing community transmission of Ebola virus by providing more immediate protection than

22 a venous blood specimen tested negative for Ebola virus by quantitative reverse-transcription polyme

23 Recent studies have shown that Ebola virus can persist in wastewater.

24 Ebola virus causes devastating hemorrhagic fever outbrea

25 ndicated that this mutation was not found in Ebola virus clinical samples.

26 Asymptomatic infection with Ebola virus could contribute to population immunity, red

27 ogether, the evidence strongly suggests that Ebola virus delta peptide is a viroporin and that it may

28 We show here that the Ebola virus delta peptide, a conserved nonstructural pro

29 nt observations indicate that replication of Ebola virus depends on this fifth level.

30 irus, and 8 CFU of Escherichia coli carrying Ebola virus-derived plasmids.

31 r (SPM) has been developed and evaluated for Ebola virus detection.

32 d of March 2016, the West Africa epidemic of Ebola virus disease (Ebola) had resulted in a total of 2

33 es of 697/1054 children testing negative for Ebola virus disease (EVD) and accompanying caregivers.

34 data on the characteristics of patients with Ebola virus disease (EVD) and clinical management of EVD

35 al health, trauma, and personal exposures to Ebola virus disease (EVD) and health behaviors in post-c

36 are personnel (HCP) caring for patients with Ebola virus disease (EVD) are at increased risk for infe

37 The 2014-15 Ebola virus disease (EVD) epidemic strained health syste

38 The west Africa Ebola virus disease (EVD) epidemic was extraordinary in

39 ata are lacking on pregnancy outcomes during Ebola virus disease (EVD) epidemics.

40 rs from the 2013-16 west African outbreak of Ebola virus disease (EVD) has raised several new issues:

41 he clinical and virologic characteristics of Ebola virus disease (EVD) in children have not been thor

42 isual impairment in a cohort of survivors of Ebola virus disease (EVD) in Monrovia, Liberia.

43 In the wake of the recent outbreak of Ebola virus disease (EVD) in several African countries,

44 onvalescent plasma (CP) for the treatment of Ebola virus disease (EVD) in the current outbreak, predo

45 the semen of a large number of survivors of Ebola virus disease (EVD) in Western Africa may contribu

46 to characterize epidemiological patterns of Ebola virus disease (EVD) infections during the West Afr

47 Ebola virus disease (EVD) is a contagious, severe and of

48 Ebola virus disease (EVD) is a highly lethal condition f

49 Ebola virus disease (EVD) is a serious illness with mort

50 Ebola virus disease (EVD) is a severe viral illness caus

51 The pathogenesis of human Ebola virus disease (EVD) is complex.

52 ore, rapid, accurate, and early diagnosis of Ebola virus disease (EVD) is critical to public health c

53 The worst Ebola virus disease (EVD) outbreak in history has result

54 , 2016, all known transmission chains of the Ebola virus disease (EVD) outbreak in west Africa had be

55 Despite the magnitude of the Ebola virus disease (EVD) outbreak in West Africa, there

56 The West African Ebola virus disease (EVD) outbreak was the largest EVD o

57 ontributed to the sizable toll of the recent Ebola virus disease (EVD) outbreak.

58 The unprecedented 2014 epidemic of Ebola virus disease (EVD) prompted an international resp

59 EBOV) persistence in asymptomatic humans and Ebola virus disease (EVD) sequelae have emerged as signi

60 ng the unparalleled West African outbreak of Ebola virus disease (EVD) that began in late 2013, the l

61 e safety and efficacy of vaccines to prevent Ebola virus disease (EVD) were unknown when the incidenc

62 infectious it could explain re-emergences of Ebola virus disease (EVD) without known contact.

63 uct, has been developed for the treatment of Ebola virus disease (EVD), but its efficacy and safety i

64 s between deforestation and the emergence of Ebola virus disease (EVD), however, is still missing.

65 t more than 30 000 individuals have acquired Ebola virus disease (EVD), the medical and scientific co

66 trol of virus replication, viremia and fatal Ebola virus disease (EVD).

67 eptide, that is produced in abundance during Ebola virus disease (EVD).

68 n the semen of men after their recovery from Ebola virus disease (EVD).

69 ent [ACT]) for all contacts of patients with Ebola virus disease (in terms of administration and aver

70 ance for use of post-exposure prophylaxis in Ebola virus disease and identify the priorities for futu

71 ul vaccination platform in a rodent model of Ebola virus disease and that GP1 N-glycan loss does not

72 Inadequate access to rapid testing for Ebola virus disease during the 2014-to-2016 outbreak led

73 ach indicator across three time periods: pre-Ebola virus disease epidemic (January, 2013, to February

74 nt of international responders, few cases of Ebola virus disease have been diagnosed in this group.

75 We regarded samples to be positive for Ebola virus disease if the cycle threshold was 40 or low

76 ested the effect of rVSV-ZEBOV in preventing Ebola virus disease in contacts and contacts of contacts

77 e primary analysis compared the incidence of Ebola virus disease in eligible and vaccinated individua

78 five species in the genus are known to cause Ebola Virus Disease in humans.

79 In 1976, the first cases of Ebola virus disease in northern Democratic Republic of t

80 re we describe clinicopathologic features of Ebola virus disease in pregnancy.

81 py provided no benefit for the prevention of Ebola virus disease in rhesus macaques with regards to r

82 The massive outbreak of Ebola virus disease in west Africa between 2013 and 2016

83 The recent epidemic of Ebola virus disease in West Africa resulted in an unprec

84 Ebola virus disease is a serious illness of humans and n

85 rom all 117 clusters showed that no cases of Ebola virus disease occurred 10 days or more after rando

86 No cases of Ebola virus disease occurred 10 days or more after rando

87 No secondary cases of Ebola virus disease occurred among the vaccinees.

88 We sought to quantify the consequences of Ebola virus disease on maternal and child health service

89 indicators significantly declined during the Ebola virus disease outbreak in 2014.

90 The 2013-16 Ebola virus disease outbreak in west Africa was associat

91 In the post-Ebola virus disease outbreak period, vaccination coverag

92 Compared with pre-Ebola virus disease outbreak trends, significant decreas

93 In the months before the Ebola virus disease outbreak, all three maternal indicat

94 d by public health officials when addressing Ebola virus disease outbreaks in countries and seasons w

95 d safely implemented at scale in response to Ebola virus disease outbreaks in rural settings.

96 This description of the clinical features of Ebola virus disease over the duration of illness in chil

97 sts a critical role for the delta peptide in Ebola virus disease pathology and as a possible target f

98 that it may be a novel, targetable aspect of Ebola virus disease pathology.IMPORTANCE During the unpa

99 e equipment (PPE) during care activities for Ebola virus disease patients has not yet been characteri

100 The 2014 west African epidemic of Ebola virus disease posed a major threat to the health s

101 Ebola virus disease poses a global health threat.

102 e causative agent of the largest outbreak of Ebola Virus Disease recorded.

103 laria treatment to contacts of patients with Ebola virus disease should be considered by public healt

104 Ebola virus has been detected in semen of Ebola virus disease survivors after recovery.

105 As of May 6, 2016, 466 Ebola virus disease survivors had enrolled in the progra

106 The West African outbreak of Ebola virus disease that peaked in 2014 has caused more

107 liver, the characteristic histopathology of Ebola virus disease was not observed, and this absence o

108 In March, 2016, a flare-up of Ebola virus disease was reported in Guinea, and in respo

109 ugh August 2016, 256343 specimens tested for Ebola virus disease were captured in the database.

110 The rVSVDeltaG-ZEBOV-GP vaccine prevented Ebola virus disease when used at 2 x 107 plaque-forming

111 Patients recovering from Ebola virus disease who do not meet the case definition

112 y outcome was a laboratory confirmed case of Ebola virus disease with onset 10 days or more from rand

113 In survivors of Ebola virus disease, clinical sequelae including uveitis

114 es in the provision of care to patients with Ebola virus disease, including absence of pre-existing i

115 in Africa, Crimean-Congo haemorrhagic fever, Ebola virus disease, Lassa fever, and Marburg virus dise

116 After confirmation of a case of Ebola virus disease, we definitively enumerated on a lis

117 inform optimal care in a future outbreak of Ebola virus disease, we employed the Grading of Recommen

118 -ZEBOV offers substantial protection against Ebola virus disease, with no cases among vaccinated indi

119 dead bodies meeting the case definitions for Ebola virus disease.

120 cy of interferons (IFNs) in animal models of Ebola virus disease.

121 e) in the prevention of laboratory confirmed Ebola virus disease.

122 lowing the confirmation of the first case of Ebola virus disease.

123 hase 2 clinical development for treatment of Ebola virus disease.

124 ter postexposure prophylaxis; none developed Ebola virus disease.

125 g diseases, such as Zika virus infection and Ebola virus disease.

126 ltaG-ZEBOV-GP vaccine in persons at risk for Ebola virus disease.

127 at modulate the inflammatory response during Ebola virus disease.

128 ated cytokine response that is a hallmark of Ebola virus disease.IMPORTANCE Understanding how the hos

129 classified in a genus distinct from that of Ebola virus (EBOV) (genera Marburgvirus and Ebolavirus,

130 Ebola virus (EBOV) and Reston virus (RESTV) are members

131 Both Ebola virus (EBOV) and Reston virus (RESTV) cause diseas

132 Immune responses in survivors of Ebola virus (EBOV) and Sudan virus (SUDV) infections hav

133 Ebola virus (EBOV) causes severe systemic disease in hum

134 Rapid Ebola virus (EBOV) detection is crucial for appropriate

135 Diagnosis of Ebola virus (EBOV) disease (EVD) requires laboratory tes

136 Containment limited the 2014 Nigerian Ebola virus (EBOV) disease outbreak to 20 reported cases

137 The 2013-2016 West African Ebola virus (EBOV) disease outbreak was the largest filo

138 A 9-month-old infant died from Ebola virus (EBOV) disease with unknown epidemiological

139 Aware of the rapid spread of Ebola virus (EBOV) during the current West African epide

140 The recent Ebola virus (EBOV) epidemic in West Africa demonstrates

141 The Ebola virus (EBOV) epidemic in West Africa increased the

142 The Ebola virus (EBOV) genome encodes a partly conserved 40-

143 We investigated one nonsynonymous mutation, Ebola virus (EBOV) glycoprotein (GP) mutant A82V, for it

144 The Ebola virus (EBOV) GP gene encodes two glycoproteins.

145 on of a safe and efficacious vaccine against Ebola virus (EBOV) has proven elusive so far, but variou

146 Ebola virus (EBOV) infection is characterized by sporadi

147 A hallmark of Ebola virus (EBOV) infection is the formation of viral i

148 Nonhuman primate (NHP) models of Ebola virus (EBOV) infection primarily use parenteral or

149 of EVD survival in which the patient cleared Ebola virus (EBOV) infection without experimental drugs

150 rposes-proved disappointing in tests against Ebola virus (EBOV) infection, more recently, specific mo

151 s have shown promise for treatment of lethal Ebola virus (EBOV) infections, but their species-specifi

152 tion of EBOV VP40-mediated egress.IMPORTANCE Ebola virus (EBOV) is a high-priority, emerging human pa

153 Ebola virus (EBOV) is a member of the Filoviridae family

154 Ebola virus (EBOV) is a single-stranded negative-sense R

155 Ebola virus (EBOV) is an enveloped negative-sense RNA vi

156 Ebola virus (EBOV) isolates derived directly from human

157 The recent Ebola virus (EBOV) outbreak in West Africa was the large

158 The recent 2014-2016 Ebola virus (EBOV) outbreak prompted increased efforts t

159 rn, as exemplified by the recent devastating Ebola virus (EBOV) outbreak.

160 Despite sporadic outbreaks of Ebola virus (EBOV) over the last 4 decades and the recen

161 Ebola virus (EBOV) persistence in asymptomatic humans an

162 Ebola virus (EBOV) poses a significant threat to human h

163 Recent studies have suggested that Ebola virus (EBOV) ribonucleic acid (RNA) potentially pr

164 Ebola virus (EBOV) RNA persistence in semen, reported se

165 Ebola virus (EBOV) survivors are affected by a variety o

166 re on diagnostic test results and infectious Ebola virus (EBOV) titers.

167 Ferrets were also infected with Ebola virus (EBOV) to confirm their susceptibility to an

168 The Ebola virus (EBOV) variant Makona (which emerged in 2013

169 irulence and/or transmission of West African Ebola virus (EBOV) variants, which are divergent from th

170 The interaction of Ebola virus (EBOV) VP24 protein with host karyopherin al

171 rabies virus (RABV) vectored vaccine against Ebola virus (EBOV), a major threat to wild chimpanzees a

172 Ebola virus (EBOV), a member of the Filoviridae family,

173 of the Filoviridae family that also includes Ebola virus (EBOV), causes lethal hemorrhagic fever with

174 s in vitro infection of mammalian cells with Ebola virus (EBOV), Tacaribe arenavirus, and human herpe

175 s and vaccines against the highly pathogenic Ebola virus (EBOV), the cellular mechanisms involved in

176 ers are at particular risk of infection with Ebola virus (EBOV).

177 se (EVD) is a severe viral illness caused by Ebola virus (EBOV).

178 he highly glycosylated glycoprotein spike of Ebola virus (EBOV-GP1,2) is the primary target of the hu

179 Although the Ebola virus envelope glycoprotein (GP1,2) antagonizes th

180 recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVDeltaG-ZE

181 recombinant vesicular stomatitis virus-Zaire Ebola virus envelope glycoprotein vaccine (rVSVG-ZEBOV-G

182 The 2014 west African Zaire Ebola virus epidemic prompted worldwide partners to acce

183 cination success.IMPORTANCE The West African Ebola virus epidemic was the largest to date, with more

184 rus throughout the region by analysing 1,610 Ebola virus genomes, which represent over 5% of the know

185 sent words of the human genome were found in Ebola virus genomes.

186 Based on the mutation rates for Ebola virus given its natural sequence evolution, these

187 adenovirus 3 vector vaccine expressing Zaire Ebola virus glycoprotein (ChAd3-EBO-Z).

188 Recent studies demonstrate that the Ebola virus glycoprotein (GP) acquired an A82V change du

189 n reaction (rRT-PCR), using assays targeting Ebola virus glycoprotein and nucleoprotein.

190 th modified vaccinia Ankara expressing Zaire Ebola virus glycoprotein and other filovirus antigens (M

191 efficacy of VSVDeltaG pseudovirions bearing Ebola virus glycoprotein as a vaccine platform.

192 ca, recombinant, infectious VSV encoding the Ebola virus glycoprotein effectively prevented virus-ass

193 We found that wild-type Ebola virus glycoprotein, in the context of this platfor

194 ent and the activation of NF-kappaB by BST2, Ebola virus GP does not inhibit NF-kappaB signaling even

195 Ebola virus GP1,2, the Ebola virus matrix protein VP40,

196 Ebola virus has been detected in semen of Ebola virus di

197 Ebola virus has been detected in the semen of men after

198 Ebola virus has been isolated by cell culture from blood

199 tbreaks involving enveloped viruses, such as Ebola virus, have raised questions regarding the persist

200 rgence of chikungunya virus, Zika virus, and Ebola virus highlights the struggles to contain outbreak

201 assessed the seroprevalence of antibodies to Ebola virus in a cross-sectional study of household cont

202 Sexual transmission of Ebola virus in Liberia has now been documented and assoc

203 ells, the new device and protocol can detect Ebola virus in raw blood with clinically relevant sensit

204 The level of neutralizing antibodies against Ebola virus in the plasma was unknown at the time of adm

205 wever, there is concern about persistence of Ebola virus in the reproductive tract of men who have su

206 Africa or were exposed to and infected with Ebola virus in West Africa and had onset of illness and

207 unprecedented overseas intervention against Ebola virus in west Africa, dispatching 1200 workers, in

208 ptomatic disease caused by either Marburg or Ebola viruses in bats, spillover of these viruses into h

209 All blood samples from suspected Ebola virus-infected patients admitted to the Medecins S

210 Clinical outcome in laboratory-confirmed Ebola virus-infected patients was analyzed as a function

211 tinguishing feature in clinical chemistry of Ebola virus-infected patients was the elevation in alani

212 Ebola virus-infected patients were 20% more likely to su

213 et of illness and laboratory confirmation of Ebola virus infection in Europe or the United States, an

214 tissue damage in fatal EVD, and suggest that Ebola virus infection may induce aberrant neutrophils wh

215 bola virus-positive woman was diagnosed with Ebola virus infection on her first day of life.

216 from all patients with laboratory-confirmed Ebola virus infection who received care in U.S. and Euro

217 or amplify proinflammatory signaling during Ebola virus infection, potentially contributing to the d

218 asures for post-exposure prophylaxis against Ebola virus infection.

219 and translate it into treatment options for Ebola virus infection.

220 ed intracellular cholesterol trafficking and Ebola virus infection.

221 tic efficacy in a non-human primate model of Ebola virus infection.

222 ca experienced an unanticipated explosion of Ebola virus infections.

223 prioritized this compound for testing in the Ebola virus intramuscular rhesus macaque challenge model

224 Developing effective vaccines against Ebola virus is a global priority.

225 Development of an effective vaccine against Ebola virus is of high priority.

226 The frequency of asymptomatic infection with Ebola virus is unclear: previous estimates vary and ther

227 degree of sequence conservation among GP of Ebola viruses, it would be challenging to determine the

228 tigen detection of infections from Lassa and Ebola viruses (LASV and EBOV, respectively).

229 ults, MDMs treated with inactivated EBOV and Ebola virus-like particles (VLPs) induced NF-kappaB acti

230 Pre-treatment geometric mean Ebola virus load in the 14 TKM-130803 recipients was 2.2

231 against lethal challenge with mouse-adapted Ebola virus (ma-EBOV) in a dose-dependent manner.

232 Ebola virus Makona (EBOV-Makona; from the 2013-2016 West

233 et al show that the erratum to our report on Ebola virus Makona evolution not only corrected sample d

234 IFNs are weak inhibitors of Ebola virus Makona in these cell lines.

235 ombinant vesicular stomatitis virus encoding Ebola virus Makona variant GP1,2 (rVSV-MAK-GP) and obser

236 We studied cynomolgus macaques exposed to Ebola virus Makona via different routes with the intent

237 ion, we showed that Marburg virus Angola and Ebola virus Makona-WPGC07 efficiently replicated at 37 d

238 es, including dengue virus, West Nile virus, Ebola virus, Marburg virus, and Zika virus.

239 Ebola virus GP1,2, the Ebola virus matrix protein VP40, and BST2 are at least a

240 We found that the Ebola virus matrix protein, VP40, and envelope glycoprot

241 gram averaging to determine the structure of Ebola virus nucleocapsid within intact viruses and recom

242 tracellular trafficking of pathogens such as Ebola virus or bacterial toxins (e.g., cholera toxin).

243 The 2014 Zaire Ebola virus outbreak highlighted the need for a safe, ef

244 The recent Ebola virus outbreak in West Africa clearly demonstrated

245 elucidate the determinants of host-specific Ebola virus pathogenicity.

246 A neonate born to an Ebola virus-positive woman was diagnosed with Ebola viru

247 In this study, we examined whether Ebola virus proteins affect BST2-mediated induction of N

248 ons, activated NF-kappaB in concert with the Ebola virus proteins at least as effectively as wild-typ

249 Activation of NF-kappaB by the Ebola virus proteins either alone or together with BST2

250 transcription factor NF-kappaB, responds to Ebola virus proteins.

251 IFNs and, during the most recent outbreak of Ebola virus, questions regarding the suitability of the

252 Inclusion criteria were positive Ebola virus reverse transcription PCR (RT-PCR) test, age

253 Duration of detection of Ebola virus RNA by real-time RT-PCR varies by individual

254 Median duration of Ebola virus RNA detection was 158 days after onset (73-1

255 brary of short, terminally labeled probes to Ebola virus RNA followed by click assembly and analysis

256 d to improve amplification-free detection of Ebola virus RNA from blood.

257 ict that 50% and 90% of male survivors clear Ebola virus RNA from seminal fluid at 115 days (90% pred

258 -series data showed a mean clearance rate of Ebola virus RNA from seminal fluid of -0.58 log units pe

259 INTERPRETATION: Time to clearance of Ebola virus RNA from seminal fluid varies greatly betwee

260 redicted that the number of men positive for Ebola virus RNA in affected countries would decrease fro

261 These data showed the long-term presence of Ebola virus RNA in semen and declining persistence with

262 nt over time, we found that concentration of Ebola virus RNA in semen during recovery is remarkably h

263 We report the presence of Ebola virus RNA in semen in a cohort of survivors of EVD

264 This study modeled the presence of Ebola virus RNA in the semen of male Ebola survivors par

265 stical modelling to describe the dynamics of Ebola virus RNA load in seminal fluid, including clearan

266 CSF Ebola virus RNA slowly declined and was undetectable fol

267 llow-up every 3-6 weeks, which we tested for Ebola virus RNA using quantitative real-time RT-PCR.

268 Ebola virus RNA was detected in 86 semen specimens from

269 Ebola virus RNA was detected in the semen of all 7 men w

270 by enhancing the hybridization of the target Ebola virus RNA with capture probes bound to the beads.

271 Semi-quantitative Ebola virus RT-PCR (results expressed in "cycle threshol

272 Here we report Ebola virus RT-PCR data for body site and fluid samples

273 n with 0.5% Tween-20 against a high titer of Ebola virus (species Zaire ebolavirus) variant Makona in

274 virus clearance, survivors mounted a robust Ebola-virus-specific T cell response.

275 consistently found mutated in rodent-adapted Ebola virus strains.

276 sed mortality risk in patients infected with Ebola virus, supporting empirical malaria treatment in E

277 ed 24 hours previously with a lethal dose of Ebola virus suppressed viral loads by more than 5 logs a

278 Antibodies targeting the Ebola virus surface glycoprotein (EBOV GP) are implicate

279 Understanding how the Ebola virus surface glycoprotein functions to facilitate

280 istribution generated by each system, spiked Ebola virus surrogates (MS2 and Phi6) into each system,

281 We evaluated the potential for Ebola virus surrogates to be aerosolized from three type

282 ite and fluid samples from a large cohort of Ebola virus survivors at clinic follow-up.

283 say reliably detected as few as 20 copies of Ebola virus templates in both human serum and saliva and

284 pment and evaluation of the Idylla prototype Ebola virus test, a fully automated sample-to-result mol

285 the dispersal, proliferation and decline of Ebola virus throughout the region by analysing 1,610 Ebo

286 es seem to be required for the adaptation of Ebola viruses to a new species.

287 The Ebola virus transmits a highly contagious, frequently fa

288 urine, and vaginal specimens for presence of Ebola virus using RT-PCR.

289 current overview of progress in the field of Ebola virus vaccine development.

290 ed by the Makona variant compared with other Ebola virus variants was lacking.

291 istinct oligomeric states of the Marburg and Ebola virus VP35 proteins may explain differences betwee

292 Although Ebola virus VP40 and GP both activate NF-kappaB independ

293 Testing for Ebola virus was done by real-time PCR and for malaria by

294 013-2016 West African epidemic caused by the Ebola virus was of unprecedented magnitude, duration and

295 This Ebola virus was the Zaire strain of the virus family Fil

296 ive assay showed asymptomatic infection with Ebola virus was uncommon despite high exposure.

297 orresponding to 120 cDNA molecules of L-gene Ebola virus with a limit of detection of 33 cDNA molecul

298 r the species Zaire ebolavirusIMPORTANCE The Ebola virus (Zaire) species is the most lethal species o

299 Before vaccination, Zaire Ebola virus (ZEBOV)-glycoprotein (GP)-specific and ZEBOV

300 essing the glycoprotein of a Zaire strain of Ebola virus (ZEBOV).